Clinical trial

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302)

NCT06612151

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2024-12-17

PhasePHASE3

Study timeline

Study start (actual)2024-12-17Date precision: day

Registry last updated2026-09-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Small Cell Lung Cancerunresolved

Interventions

YL201DRUG

topotecan hydrochloride for injectionDRUG

Sponsors & collaborators

MediLink Therapeutics (Suzhou) Co., Ltd.lead sponsor

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06612151 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.